Age, y | 13 (8.5, 15) | Â | ||
Sex, female | 6 (30%) | Â | ||
Comorbidities | Â | Â | ||
 Neurology | 10 (50%) |  | ||
 Oncology | 3 (15%) |  | ||
 Respiratory | 2 (10%) |  | ||
 Genitourinary | 2 (10%) |  | ||
 Diabetology | 2 (10%) |  | ||
 Cardiology | 1 (5%) |  | ||
 Gastrointestinal | 1 (5%) |  | ||
 None | 6 (30%) |  | ||
Sepsis, proven | 15 (75%) | Â | ||
Sepsis, suspected | 5 (25%) | Â | ||
Pathogens | Â | Â | ||
 Gram-negative bacteria | 7 (35%) |  | ||
 Gram-positive bacteria | 4 (20%) |  | ||
 Viral | 3 (15%) |  | ||
 Fungal | 2 (10%) |  | ||
 Unknown | 6 (30%) |  | ||
CXR abnormalities, present | 14 (70%) | Â | ||
Source of Pathogen | Â | Â | ||
 Respiratory | 11 (55%) |  | ||
 Cardiovascular | 4 (20%) |  | ||
 Gastrointestinal | 2 (10%) |  | ||
 Genitourinary | 1 (5%) |  | ||
 Wound | 1 (5%) |  | ||
 Unknown | 1 (5%) |  | ||
PRISM III score | 5 (3, 13.25) | Â | ||
PIM-2 mortality risk | -3.96 (-4.44, -3.17) | Â | ||
PELOD-2 score, initial | 11 (4, 18) | Â | ||
PELOD-2 score, highest | 12 (11, 21) | Â | ||
GCS on admission | 13 (6, 15) | Â | ||
Invasive Ventilation | 11 (55%) | Â | ||
Non-Invasive Ventilation | 4 (20%) | Â | ||
Inotrope/vasopressor administered | 17 (85%) | Â | ||
PICU days | 4.5 (1.25, 10) | Â | ||
Hospital days | 15.5 (9, 35.75) | Â |